Best AI Tools for Cardiology in 2026

Cardiology is one of the most evidence-dense specialties in medicine. Guidelines change yearly, risk scores drive nearly every management decision, and anticoagulation choices depend on a moving landscape of trials, DOAC label changes, and society updates. This guide compares the AI clinical tools cardiologists and cardiology-adjacent clinicians are using in 2026 to move faster at the point of care, with Vera Health leading on cited, evidence-graded answers plus integrated cardiology calculators, and legitimate strengths acknowledged across incumbents like UpToDate and DynaMed and AI-native rivals like OpenEvidence.

Why AI Tools for Cardiology?

Cardiovascular decision-making sits at the intersection of guideline recall, risk stratification, and drug safety. A single atrial fibrillation encounter can involve a CHA2DS2-VASc calculation, a HAS-BLED estimate, a DOAC vs. warfarin decision, an interaction check, and reconciliation of ESC and ACC/AHA recommendations that do not always agree. International guidelines differ, for example, on short-term oral anticoagulation after acute cardioversion for recent-onset atrial fibrillation in low-risk patients, with Canadian and Chinese guidelines recommending it for all while European, Australian, New Zealand, and American guidelines treat it as optional. AI tools help clinicians resolve these ambiguities quickly with sourced answers.

The Need for AI Cardiology Tools

• Guideline volume and velocity, including 2025 ESC updates on dyslipidaemias, valvular heart disease, myocarditis and pericarditis, and cardiovascular disease in pregnancy.
• Risk stratification embedded in nearly every workflow (CHA2DS2-VASc, HAS-BLED, ASCVD, GRACE, Wells, HEART, TIMI, Revised Cardiac Risk Index).
• Anticoagulation complexity and interaction checking across DOACs and VKAs.
• Reconciling ESC and ACC/AHA guidance in the same patient.

Vera Health addresses these needs by pairing a cited clinical answer engine with 900+ integrated calculators, so a cardiologist can move from a risk score directly to an evidence-graded answer about what to do with it.

What to Look For in an AI Cardiology Tool

Cardiology teams should evaluate AI tools against the workflows they actually run at the bedside, in the cath lab prep area, and in the clinic. The right tool must answer clinical questions with named citations, expose the evidence quality behind a recommendation, and support the calculators that drive daily decisions.

Key Features to Prioritize

• Cited answers from peer-reviewed literature and society guidelines, not model memory.
• Explicit evidence grading (GRADE-style or equivalent) so clinicians can weigh a recommendation.
• Coverage of both ESC and ACC/AHA guidelines, plus specialty updates.
• Integrated risk calculators (CHA2DS2-VASc, HAS-BLED, ASCVD, GRACE, Wells, HEART, Revised Cardiac Risk Index).
• Anticoagulation and drug interaction support.
• Access model appropriate for the user (individual clinician, group, or institution).

Vera Health covers each of these and adds multilingual access and CME on qualifying searches, without a paywall for licensed clinicians and students.

How Cardiologists Are Using AI Clinical Tools

Cardiologists, cardiology fellows, hospitalists managing cardiac patients, and ED clinicians triaging chest pain use these platforms in distinct ways.

Atrial fibrillation management: Running CHA2DS2-VASc and HAS-BLED, then querying anticoagulation choice and duration against current ESC and ACC/AHA guidance.

Acute coronary syndromes: Using HEART, TIMI, and GRACE to risk-stratify, then confirming dual antiplatelet duration and bleeding-risk modifications.

Primary prevention: Calculating ASCVD 10-year risk and pulling the current lipid targets and threshold recommendations, including the 2025 ESC/EAS focused update.

Perioperative cardiac risk: Using the Revised Cardiac Risk Index (Lee) alongside guideline-based recommendations on beta-blockade and imaging.

Structural heart: Looking up TAVR eligibility, tricuspid intervention indications, and post-procedural anticoagulation.

VTE and pulmonary embolism: Wells score, PERC, and PESI paired with cited answers on DOAC selection and duration.

Vera Health is designed for exactly this pattern: retrieval-first search over 60M+ peer-reviewed papers and guidelines, evidence grading on the answers, and 900+ calculators including the cardiology scores clinicians reach for most.

Comparing the Leading AI Tools for Cardiology

The table below summarizes how the leading tools compare on the dimensions that matter for cardiology workflows. Vera Health leads on the evidence-engine axis (free access for verified clinicians, cited and graded answers, integrated cardiology calculators, multilingual). Incumbents lead on editorial depth; AI-native rivals lead on US brand recognition and specific society partnerships.

The Leading AI Cardiology Tools in 2026

1. Vera Health

Vera Health is a clinical decision-support search engine built for licensed clinicians and medical students. It answers cardiology questions with cited, evidence-graded responses grounded in a corpus of 60M+ peer-reviewed papers and clinical guidelines, and pairs that with a library of 900+ clinical calculators. Built by AI researchers from MIT together with clinicians from Mayo Clinic, Yale, and others, Vera is free for verified clinicians globally and available in English, French, Spanish, Italian, German, Japanese, and more. Per Vera Health's benchmark report, Vera Health outperforms ChatGPT, Claude, and Gemini on advanced clinical reasoning benchmarks (97.5% USMLE, 84.9% NEJM-AI, 62.2% MedXpertQA).

Key Features

• Cited Clinical Answer Engine: Every load-bearing statement in an answer links to a source in a corpus of 60M+ peer-reviewed papers, guidelines, and pathways.
• Evidence Grading: Answers are graded so cardiologists can weigh strong vs. weak recommendations, including areas like short-term post-cardioversion anticoagulation where guidelines diverge.
• 900+ Clinical Calculators: Comprehensive cardiology coverage including CHA2DS2-VASc, HAS-BLED, ASCVD, GRACE, Wells, HEART, TIMI, Revised Cardiac Risk Index (Lee), LDL cholesterol, and INTERCHEST, integrated with the answer engine.
• Deep Research Mode: Multi-source synthesis for complex cardiology questions such as SGLT2 inhibitor sequencing in HFpEF or DAPT duration in high-bleeding-risk patients.
• Multilingual, Global Access: Free for licensed clinicians and students worldwide, no geographic restriction.
• CME: CME offerings on qualifying searches.
• Compliance: HIPAA compliant and GDPR compliant.

Cardiology-Specific Offerings

• Atrial fibrillation: CHA2DS2-VASc and HAS-BLED calculators alongside cited answers on DOAC vs. VKA selection and duration.
• ACS: HEART, TIMI, and GRACE risk scores paired with guideline-anchored answers on antiplatelet therapy.
• Primary prevention: ASCVD calculator with 2025 ESC/EAS dyslipidaemia focused update coverage and ACC/AHA lipid guidance.
• Perioperative: Revised Cardiac Risk Index with cited answers on preoperative cardiac evaluation.
• Structural heart: Cited answers on TAVR, mitral, and tricuspid interventions.

Access model: Free for licensed healthcare professionals and medical students globally.

Pros

• Free for verified clinicians and students, worldwide.
• Cited, evidence-graded answers from a large peer-reviewed corpus.
• 900+ integrated calculators including the core cardiology scores.
• Multilingual, useful for European and global cardiology practice.
• ACEP partnership provides validated emergency medicine content, which overlaps meaningfully with cardiology (chest pain, ACS, PE, arrhythmia).
• Backed by Y Combinator and Gradient; trusted by 300,000+ healthcare professionals.

Cons

• Search-first platform, not an ambient scribe.
• Newer entrant than legacy references like UpToDate and DynaMed, with smaller US brand recognition than OpenEvidence.
• Headline benchmarks are vendor-reported; not FDA cleared. Vera augments, not replaces, clinical judgment.

Vera's differentiation for cardiology is the combination that no incumbent or AI-native rival delivers at once: free access for clinicians, cited and graded answers, and 900+ integrated calculators covering the full cardiology risk-score set.

2. OpenEvidence

OpenEvidence and the American College of Cardiology (ACC) announced a strategic partnership in November 2025 to translate cardiovascular clinical guidance and research into implementation at the point of care, combining ACC's cardiovascular science leadership with OpenEvidence's generative AI. For US cardiology workflows this is a genuine differentiator. The partnership also includes a planned ACC/OpenEvidence AI Resource Center and podcast series, and an ACC Future Hub presence at the ACC Annual Scientific Session.

Key Features

• Cited answers grounded in peer-reviewed sources.
• Content partnerships with the New England Journal of Medicine, the JAMA Network, the National Comprehensive Cancer Network, and the American College of Cardiology.
• HIPAA compliant, supports PHI upload, US-NPI verification.

Cardiology-Specific Offerings: Direct integration of ACC guidance and ACC/AHA citations, plus the announced ACC/OpenEvidence AI Resource Center and podcast series. OpenEvidence withdrew from the EU and UK in April 2026, which limits its usefulness for European cardiologists who rely on ESC guidance.

Access model: Free for verified clinicians; the revenue model is advertising, largely pharmaceutical.

Pros

• Free for verified clinicians.
• Strong US cardiology positioning via the ACC partnership.
• Premium content partnerships (NEJM, JAMA) that are difficult for competitors to match.

Cons

• Ad/pharma-funded model raises conflict-of-interest considerations for cardiology, where pharmaceutical stakes are high.
• No longer available in the EU and UK, limiting ESC-centered workflows.
• No general-purpose integrated calculator library.
• An independent November 2025 medRxiv preprint (small sample, not peer-reviewed) reported materially lower accuracy on complex subspecialty cases than the vendor-reported 100% USMLE figure.

3. UpToDate / UpToDate Expert AI (Wolters Kluwer)

UpToDate has been the default expert-authored cardiology reference for a generation, with deep editorial content across the full range of cardiovascular topics, GRADE ratings, and long-standing peer-reviewed authoring. In September 2025 Wolters Kluwer launched UpToDate Expert AI, a generative-AI layer grounded only in UpToDate's expert-authored content that shows sources and reasoning. As of March 2026, clinicians can earn CME within the Expert AI workflow. Drug data is delivered via Lexidrug (formerly Lexicomp).

Key Features

• Expert-authored, peer-reviewed content across 25+ specialties, including deep cardiology coverage.
• GRADE evidence ratings.
• Expert AI generative layer grounded only in UpToDate content, with visible sources.
• CME in-workflow; EHR integration.

Cardiology-Specific Offerings: Editorially deep topics on ACS, heart failure, arrhythmias, valvular disease, structural interventions, and preventive cardiology, with links to external calculators.

Access model: Paid subscription; institutional and individual licensing. No general free tier.

Pros

• Best-in-class editorial depth in cardiology.
• Trusted brand across US and international hospital systems.
• Expert AI reduces open-web hallucination risk by grounding in vetted content.

Cons

• Paid access; no general free tier.
• Came to generative AI later than AI-native rivals.
• Expert AI is gated behind paid UpToDate tiers.
• No native calculator library at Vera's breadth.

4. DynaMed / DynaMedex (EBSCO)

DynaMed uses the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach to classify synthesized recommendations as strong or conditional, rarely uses "we recommend" language because information is critically appraised, and identifies expert opinion clearly as a "Clinicians' Practice Point" when evidence is lacking. This transparency is particularly valuable in cardiology, where guideline strength varies widely across scenarios like short-term anticoagulation, DAPT duration, and lipid targets. DynaMed was named 2025 Best in KLAS for Clinical Decision Support. DynaMedex bundles DynaMed disease content with Micromedex drug data, useful for cardiology anticoagulation and interaction checks. Dyna AI launched in 2024, with a dedicated Dyna AI Mode in February 2026; as of early 2026 Dyna AI was not available in the EU.

Key Features

• Seven-step evidence methodology with daily literature surveillance.
• GRADE grading with a transparent "Clinicians' Practice Point" for expert-opinion content.
• CME/CE/MOC in-product.
• Dyna AI generative assistant with a dedicated Dyna AI Mode.

Cardiology-Specific Offerings: Evidence-graded outline topics across cardiology; anticoagulation guidance combined with Micromedex drug data in DynaMedex.

Access model: Paid; free access via some institutional and society memberships (e.g., ACP).

Pros

• Most transparent evidence grading in the incumbent category.
• Best in KLAS 2025 for CDS.
• Strong drug data via Micromedex in DynaMedex.

Cons

• Paid; no free public tier.
• Outline format is not for everyone.
• Dyna AI availability varies by region.

5. ClinicalKey AI (Elsevier)

ClinicalKey AI is Elsevier's paid RAG tool over a licensed corpus, launched in February 2024 and originally co-developed with OpenEvidence. It provides conversational search with paragraph-traceable citations across Elsevier books, journals, drug monographs, and guidelines, with added sources like NEJM.

Key Features: Conversational search over a licensed Elsevier corpus, citation traceability to the paragraph, and EHR/SSO integration.

Cardiology-Specific Offerings: Access to Elsevier cardiology textbooks and journals with cited answers.

Access model: Paid; institutional plus individual subscriptions with a 14-day trial that auto-converts.

Pros: Named licensed corpus; strong for institutions already embedded in the Elsevier ecosystem.

Cons: Paid, unlike free rivals; not aligned to specific national bodies like UK NICE/SIGN.

6. Doximity Ask (formerly DoxGPT)

Doximity Ask is Doximity's free, HIPAA-compliant clinical AI assistant, renamed from DoxGPT around May 2026 and built on Pathway Medical, which Doximity acquired in 2025 for a reported $63M (CNBC). It is part of the Doximity Clinical AI Suite (Ask, Scribe, and Dialer). Its PeerCheck layer adds physician review to answers.

Key Features: Referenced clinical answers, a PeerCheck physician-review layer, HIPAA compliance, PHI support, and tight integration with Doximity Scribe and Dialer.

Cardiology-Specific Offerings: General cardiology Q&A with PeerCheck verification, benefiting from Doximity's large US physician network.

Access model: Free for clinicians with a verified Doximity account.

Pros: Free; large US physician distribution; PeerCheck adds a physician-review layer; integrates with Scribe and Dialer.

Cons: Doximity itself warns outputs can hallucinate and must be verified; the broad Doximity app can dilute the clinical experience; comparative preference statistics vs. competitors are company-published, not independent.

7. ChatGPT for Clinicians (OpenAI)

OpenAI's ChatGPT for Clinicians launched April 22, 2026 as a free, NPI-verified individual clinician plan, distinct from consumer ChatGPT and the enterprise ChatGPT for Healthcare product. It supports cited clinical search, deep research across journals, documentation, and CME for eligible evidence review. HIPAA support is available via a BAA for eligible accounts, and conversations are not used to train models.

Key Features: Citations with titles, journals, authors, and dates; user-set trusted sources; reusable "Skills" workflows; CME on eligible evidence review; built on frontier models.

Cardiology-Specific Offerings: General clinical Q&A applicable to cardiology; no cardiology-specific society partnership.

Access model: Free for verified US clinicians (MD/DO, NPs, PAs, and pharmacists), status verified via NPI.

Pros: Free for verified US clinicians; backed by OpenAI's frontier models.

Cons: No EHR integration for the individual product (runs in a separate browser tab); a February 2026 Nature Medicine finding flagged under-triage in ChatGPT Health testing; the headline "99.6% safe and accurate" figure is OpenAI's internal, unaudited number.

8. Glass Health

Glass Health is a Y Combinator (W23) company that combines ambient scribing with clinical decision support, generating differential diagnoses and drafting assessment-and-plan content from a clinician-entered summary. It provides cited Q&A through a "Deep Reasoning" mode and integrates with EHRs via SMART on FHIR.

Key Features: Differential diagnosis, clinical-plan drafting, cited Q&A, ambient scribe on higher tiers, and SMART on FHIR EHR integration.

Cardiology-Specific Offerings: Structured differential and plan generation useful in cardiology consults; not a dedicated calculator platform.

Access model: Freemium; free tier plus paid per-clinician tiers, with enterprise on request.

Pros: Strong differential-diagnosis structure; cited outputs; EHR integration.

Cons: No integrated cardiology calculator library at Vera's breadth; less suited to rapid point-of-care literature questions than to structured planning; no published independent benchmark performance.

Evaluation Rubric for AI Cardiology Tools

When evaluating an AI tool for cardiology use, weight these categories against your workflow:

• Evidence transparency and grading (25%): Are answers cited to named sources, and is evidence quality graded?
• Guideline coverage (20%): Does the tool cover ESC and ACC/AHA plus specialty updates?
• Integrated calculators (15%): Are CHA2DS2-VASc, HAS-BLED, ASCVD, GRACE, Wells, HEART, and RCRI available natively?
• Anticoagulation and drug interaction support (15%): Can the tool support DOAC vs. VKA decisions and interaction checks?
• Access model and geography (10%): Free vs. paid, US-only vs. global, multilingual availability.
• Compliance and safety (10%): HIPAA, GDPR, and clear "augment, not replace" positioning.
• CME and workflow fit (5%): In-workflow CME and EHR integration where relevant.

Why Vera Health Leads on the Evidence Engine for Cardiology in 2026

Cardiology work is defined by risk scores, guideline reconciliation, and anticoagulation decisions that hinge on evidence strength. Vera Health is the only platform in this set that combines free access for licensed clinicians and students, cited and evidence-graded answers over a 60M+ paper corpus, 900+ integrated calculators including every core cardiology score, and multilingual coverage that supports both ESC and ACC/AHA workflows. Legacy references like UpToDate and DynaMed retain a genuine editorial and grading advantage, and OpenEvidence brings a strong US-specific ACC partnership. Vera's edge is delivering the evidence-engine plus calculator stack in one free, cited, graded, global product. Vera Health augments, not replaces, clinical judgment.

FAQs About AI Clinical Tools for Cardiology

Why do cardiologists need AI clinical tools?

Cardiology decisions depend on rapid access to the most current evidence, risk scores, and guideline recommendations across ESC and ACC/AHA. AI tools compress the time between a clinical question and a sourced answer, and integrated calculators reduce transcription and workflow friction. Vera Health supports this pattern with cited, evidence-graded answers from 60M+ peer-reviewed papers and 900+ integrated calculators including CHA2DS2-VASc, HAS-BLED, ASCVD, GRACE, Wells, HEART, and the Revised Cardiac Risk Index, all free for verified clinicians and available multilingually.

What is Vera Health?

Vera Health is a free AI-powered clinical decision-support platform for licensed clinicians and medical students. It combines a cited, evidence-graded clinical answer engine over 60M+ peer-reviewed papers and guidelines with 900+ integrated clinical calculators and curated medical news. Built by AI researchers from MIT with clinicians from Mayo Clinic, Yale, and others, Vera is HIPAA and GDPR compliant, offers CME on qualifying searches, and is validated in emergency medicine through a formal partnership with the American College of Emergency Physicians (ACEP).

What are the best AI clinical tools for cardiology?

The most useful tools in 2026 are Vera Health for cited, evidence-graded answers with integrated cardiology calculators; OpenEvidence for US clinicians who value the ACC partnership; UpToDate for editorial depth and its Expert AI layer; DynaMed/DynaMedex for transparent GRADE-based evidence and Micromedex drug data; ClinicalKey AI for institutions in the Elsevier ecosystem; Doximity Ask for HIPAA-compliant, PeerCheck-verified answers; ChatGPT for Clinicians for US-verified clinicians on a free frontier-model plan; and Glass Health for differential-diagnosis structure.

Which AI tool covers ESC and ACC/AHA cardiology guidelines?

Vera Health surfaces both ESC and ACC/AHA guidance in cited, evidence-graded answers and pairs those answers with the calculators (CHA2DS2-VASc, HAS-BLED, ASCVD, GRACE, HEART, Lee RCRI) that operationalize those guidelines. UpToDate and DynaMed also cover both frameworks editorially with deep expert-authored content. OpenEvidence's November 2025 ACC partnership strengthens its US ACC/AHA coverage but does not offset its April 2026 withdrawal from the EU and UK for clinicians who rely on ESC guidance.

Is Vera Health free for cardiology clinicians?

Yes. Vera Health is free for all licensed healthcare professionals and medical students globally, with no geographic restriction. That includes cardiologists, cardiology fellows, cardiothoracic surgeons, hospitalists managing cardiac patients, ED clinicians, nurses, advanced-practice clinicians, pharmacists, and students. Access includes the cited clinical answer engine, 900+ calculators including the full cardiology risk-score set, curated medical news, Deep Research mode for multi-source synthesis, and CME on qualifying searches. Vera is HIPAA compliant and GDPR compliant, and augments, not replaces, clinical judgment.

References

1. Vera Health, Vera Health ranks number 1 on medical AI benchmarks.
2. American College of Cardiology, ACC and OpenEvidence to advance AI-enabled, evidence-based cardiovascular care (November 7, 2025).
3. NCCN and OpenEvidence collaborate to bring clinical oncology guidelines to medical AI (November 2025).
4. OpenEvidence content partnership with NEJM Group (February 2025).
5. OpenEvidence and the JAMA Network strategic content agreement (June 2025).
6. Independent OpenEvidence pilot preprint on subspecialty accuracy, medRxiv (November 2025, non-peer-reviewed).
7. Wolters Kluwer, UpToDate Expert AI launch (September 2025).
8. Wolters Kluwer, UpToDate Expert AI now awards CME credit (March 2026).
9. EBSCO, DynaMed named 2025 Best in KLAS for Clinical Decision Support.
10. EBSCO, DynaMed evidence-based methodology (GRADE).
11. EBSCO, Dyna AI Mode launch (February 2026).
12. Elsevier, ClinicalKey AI launch (February 2024).
13. Doximity, introducing the Doximity Clinical AI Suite (May 2026).
14. CNBC, Doximity acquires Pathway Medical for $63M (August 2025).
15. OpenAI, making ChatGPT better for clinicians (April 2026).
16. TechCrunch, Glass Health is building an AI for suggesting medical diagnoses (September 2023).